Premium
Ex vivo expansion of hematopoietic cells from umbilical cord blood for clinical transplantation
Author(s) -
Conrad Patricia D.,
Emerson Stephen G.
Publication year - 1998
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.64.2.147
Subject(s) - ex vivo , stem cell , haematopoiesis , umbilical cord , progenitor cell , transplantation , biology , immunology , bone marrow , hematopoietic stem cell , cord blood , cancer research , in vivo , medicine , microbiology and biotechnology
Stem cell transplantation (SCT) has achieved significant therapeutic success over the last 10 years, providing a viable treatment option for many previously incurable diseases. However, several inherent limitations of the procedure have restricted its widespread use. These include: lack of sufficient donors for all recipients, a period of bone marrow (BM) aplasia leading to severe, prolonged neutropenia and thrombocytopenia, and the potential for tumor contamination in autologous SCT. Umbilical cord blood (UCB) provides a unique, and potentially more successful, approach to alleviating these limitations. Ex vivo manipulation of hematopoietic stem (HSCs) and progenitor cells (HPCs) derived from UCB using a liquid culture system has revealed that the primitive HSCs from UCB are not identical to their BM counterparts. In fact, these cells may derive from a more primitive stem cell compartment. Ultimately, successful engraftment of UCB HSCs manipulated in an ex vivo environment may lead to a larger number of these life‐saving procedures being performed and the full potential of SCT realized. J. Leukoc. Biol . 64: 147–155; 1998.